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EDITORIAL
Pre-clinical screening of immunomodulatory compounds
using the parent-into-F1 model☆
Activation of the innate immune system by toll-like
receptors (TLR) provides an early response to pathogens and
shapes the subsequent antigen-specific adaptive immune
response [1]. Unmethylated cytosine-guanine dinucleotide
(CpG)motifs present in bacterial DNA, but not vertebrateDNA,
can be detected byToll like receptor 9 (TLR9)—bearingDC and
B cells resulting in a pro-inflammatory Th1 response [2–4].
Synthetic oligodeoxynucleotides (ODN) expressing these CpG
motifs exhibit similar in vivo biologic activity and have been
shown to reduce disease severity for selected pathogens, to
promote vaccine responses and to enhance anti-tumor re-
sponses (reviewed in Ref. [4]). Conversely, suppressive DNA
sequences have also been identified [4]. TTAGGG elements in
mammalian telomeric DNA and synthetic ODNs containing
these motifs can inhibit pro-inflammatory and Th1 cytokine
production [5] and have been reported as beneficial in
autoimmune conditions such as collagen-induced arthritis [6]
and lupus nephritis [7].
Microsatellite (MS) DNA is composed of short tandemly
repeated DNA sequences widely distributed in the human
genome. MS DNA has been used as a molecular marker for
DNA fingerprinting analyses and alterations in MS DNA triplet
repeats have been associated with several hereditary
diseases, primarily neurological (reviewed in Ref. [8]).
Recently, ODNs with sequences based on MS DNA have been
shown to exhibit inhibitory effects on the immune response
[9]. One of these MS DNA-mimicking ODNs with CCT repeats
(compound SATO5f) was reported to down regulate TLR7/9-
dependent interferon alpha (IFN-a) production [9] raising the
possibility that SATO5f and similar compounds may be
beneficial in conditions where increased IFN-a has a
pathogenic role e.g., lupus [10]. Data supporting this idea
are presented in the current issue where in the article by He
et al. [11], in vivo administration of SATO5f is effective in
preventing lupus-like renal disease occurring in an induced
model of murine lupus, the parent-into-F1 (p→F1) model of
chronic graft-vs.-host disease (GVHD). Administration of
SATO5f was administered twice weekly i.p. beginning at
the time of first donor cell transfer and continued for 8–
10 weeks resulted in significant reduction of autoantibodies
and ICGN severity compared to untreated chronic GVHD
mice. An intermittent dosing scheme was also effective. This
work not only supports the potential clinical application of a
new class of immunomodulatory compounds in lupus but it
also underscores the usefulness of animal models in
screening for biologic agents with therapeutic potential.
Improvement in lupus-like ICGN by a candidate compound
is the gold standard in pre-clinical animal testing. In this
regard, both spontaneous and induced murine lupus models
have been valuable. Although spontaneous lupus models such
as the MRL/lpr and female NZBxWF1 have been widely used,
a major drawback is that severe ICGN may require ~6 months
for development. In the p→F1 model, lupus-like ICGN
severity varies among the strains used [12–14] however
some strain combinations can exhibit ICGN as early as 8–
12 weeks after donor cell transfer. Moreover, unlike sponta-
neous lupus models, in the p→F1 model, the exact time of
disease onset, the initiating antigen and the pathogenic T
cells (donor CD4 T cells) are all known and the latter are of
sufficient frequency that they are readily identified by flow
cytometry without the need for custom tetramers. Together,
these features have allowed much of the kinetics of acute
and chronic GVHD pathogenesis in p→F1 mice to be
elucidated (reviewed in Ref. [14]). For example, acute
GVHD seen following the transfer of C57Bl/6 (B6) splenocytes
into (B6×DBA/2)F1 mice (B6→BDF1) results from donor CD4
and CD8 T cell recognition of host MHC II and MHC I
alloantigens respectively. Donor anti-host CD8 CTL specific
for host MHC I eliminates host lymphocytes and induces
immunodeficiency rather than autoimmunity and ICGN. By
contrast, chronic GVHD can be induced in B6→BDF1 mice
using donor splenocytes depleted of CD8 T cells indicating that
chronic GVHD results solely from donor CD4 T cell activation in
response to host allogeneicMHC II. The resulting cognateCD4 T
cell help to host B cells induces host lymphocyte expansion,
lupus specific autoantibodies and, depending on the strain
combinations, ICGN [15,16]. Moreover, acute and chronic
GVHD phenotypes can be distinguished by flow cytometry at
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2 weeks after donor cell transfer [17] allowing rapid identifi-
cation of promising compounds with immunomodulatory
potential.
In the current study by He et al., the authors used the
Balb/c→CB6F1 strain combination and administered multiple
transfers of T cell-containing lymphocytes from spleen, lymph
node and thymus. This approach has the advantage of inducing
a relatively rapid (8–10 weeks) lupus-like ICGN as opposed to
that seen following a single transfer of unfractionated Balb/c
splenocyteswhich can require 6 months for ICGN [18]. However
a single transfer of unfractionated splenocytes can induce ICGN
at 10–12 weeks if female DBA/2 (DBA) donors (containing ~12–
14×106 CD4 T cells) are transferred into female BDF1 hosts
[19]. Unlike chronic GVHD seen using CD8 depleted B6 donor
cells and BDF1 hosts, chronic GVHD in both the BALB/c→CB6F1
and theDBA→BDF1 chronic GVHD is seen despite the transfer of
donor CD8 T cells [18,20]. For both p→F1 combinations, the
donor anti-host CD8 CTL response is impaired resulting in
chronic rather than acute GVHD due to an intrinsic and possibly
anextrinsicCD8Tcell defect. For example, bothDBAandBalb/c
donor CD8 T cells have a significant reduction in the anti-
allogeneic CD8 precursor CTL frequency compared to that of B6
CD8 T cells [18,20]. Additionally, both DBA and Balb/c CD4 T
cells are strong IL-4 and weak IFN-g producers compared to B6
mice where the reverse trend is observed [21–24] raising the
possibility that defective donor anti-host CD8 CTL in DBA→BDF1
and Balb/C→CB6F1 mice is secondary to sub optimal CD4 T cell
help. Although the suboptimal DBA CD8 CTL cell response is not
required for donor CD4 T cell driven lupus-like disease in
DBA→BDF1 mice, we have recently observed that DBA donor
CD8 T cells are critical for sex-based differences (i.e. greater
female severity) in both long term ICGN [19] and in two-week
donor CD4 T cell engraftment [25] indicating a novel role of CD8
T cells in shaping sex based differences in immune function.
An important feature of the p→F1 model is that the
recipient is normal (i.e. non lupus-prone) and immunologi-
cally intact prior to donor cell transfer as opposed to GVHD
models for bone marrow transplantation where the recipient
is irradiated. Thus, in addition to modeling human lupus, the
p→F1 model is also an in vivo model of a normal ag-driven T
cell driven response. Acute GVHD in B6→BDF1 mice is a
model for normal CD8 CTL development whereas chronic
GVHD in DBA→BDF1 mice is a model for CD4 T cell activation
in the setting of a failed or impaired in vivo CD8 CTL
response. Together these two combinations have pre-clinical
value in the testing of biologically active compounds in
addition to testing for potential lupus-specific therapeutics.
For example, B6→BDF1 mice are useful for the screening of
compounds that selectively block CD8 CTL maturation
thereby converting disease phenotype from acute to chronic.
Such compounds could be of use in clinical situations where
CD8 CTL are undesirable e. g., preventing early allograft
rejection (reviewed in Ref. [14]).
Conversely, the DBA CD8 T cell abnormality can be
exploited in DBA→BDF1 mice to screen for agents with CD8
CTL promoting properties thereby converting disease pheno-
type from chronic to acute. Such compounds could be useful in
enhancing anti-tumor or anti-viral responses and may possibly
be useful in lupus. Promising candidates must then be further
examined in long term studies to ascertain whether the two-
week phenotype is maintained and that mice do not revert to
lupus-like disease long term. If reversion is seen, thismay bean
indication of the need for either additional doses of the test
compound or possibly a failure of CD8 and/or memory T cells
(see below).
Using this approach, we have observed that chronic GVHD
can be converted to acute GVHD in DBA→F1 mice by the in
vivo administration of either: a) rIL-12, b) a blocking anti-
CD80 mAb, or c) an agonist anti-CD40 mAb. Although all three
agents induce a strong DBA donor CD8 CTL and convert two-
week phenotype to acute GVHD, the mechanism involved is
different in each case. For example, rIL-12, a product of the
innate immune response, is well known as promoter of CD8
CTL [26]. Acute GVHD is induced in DBA→BDF1 mice if rIL-12
is given during the first 5 days after donor cell transfer
however the effect is lost if administration is delayed until
day 7. Thus, rIL-12 administration likely circumvents the DBA
CD8 CTL defect by providing requisite amounts of signal 3 to
newly activated donor CD8 T cells [27].
By contrast, in vivo anti-CD80mAb treatment of DBA→BDF1
mice promotes donor CD8 CTL and induces acute GVHD not by
enhancing initial activation but by impairing CD8 CTL effector
downregulation. Upregulation of CD80 and CD86 is well
described on activated T cells [28–31]. Similarly, in p→F1
mice, donor T cell upregulation of CD80, more so than CD86, is
seen by ~day 10 and acts to limit their expansion [32].
Confirming this view, donor T cells defective in CD80 exhibit
enhanced induction of acute GVHD due to greater peak CD8
CTL effector numbers [32]. Treatment of DBA→BDF1 mice
with blocking anti-CD80 mAb but not anti-CD86 mAb boosts
peak expansion of donor CD8 T cell effectors by blocking CD80
mediated effector limitation [33] resulting in acute GVHD.
These results support the idea that anti-CD80 mAb may be a
useful immunotherapeutic adjunct in clinical situations where
CD8 CTL promotion is desired such as suboptimal responses to
tumors or viruses.
Lastly, a single dose of agonist anti-CD40 mAb at the time
of donor cell transfer in DBA→BDF1 mice exhibits both T cell
and B cell stimulating properties and licenses APC thereby
bypassing the need for donor CD4 T cell help for CD8 CTL
[34]. In the short term, anti-CD40 treated DBA→BDF1 mice
exhibit acceleration of both donor CD8 CTL development and
acute GVHD phenotype compared to that seen in B6→BDF1
mice (i.e. conventional CD4 T cell help for CD8 CTL). By
12 weeks, however, anti-CD40 treated DBA→BDF1 mice
exhibit serological reversion to chronic GVHD in conjunction
with reduced numbers donor CD8 T cells and increased
numbers of host B cells compared to B6→BDF1 mice which
maintain the acute GVHD phenotype. Because memory CD8 T
cells require CD4 T cell help during priming [35], it is possible
that serologic reversion to lupus reflects a lack of memory
CD8 T cells in anti-CD40 mAb treated DBA→BDF1 mice.
Although these results do not necessarily support a thera-
peutic role for agonist anti-CD40 mAb in lupus, they raise the
novel possibility that CD8 T cells, possibly memory, are
important in maintaining lupus remission. Further studies
will be necessary to confirm these results however, they are
consistent with work in spontaneous lupus models demon-
strating an important role for CD8 T cells in downregulating
humoral autoimmunity either as CD8 Tregs [36] or as Qa-
restricted CD8 T cells which suppress T follicular helper
activity to autoreactive B cells [37,38].
With the advent of DNA based compounds with the potential
to modify both innate and adaptive immune responses, a new
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direction in the treatment of immune mediated conditions is
possible in humans. Mouse models will continue to play an
important role in identifying promising compounds and the
P→F1 model offers a number of experimental advantages. It
will be of interest to determine whether SATO5f and other MS
DNA based ODNs act to improve lupus by promoting CD8 T cells,
inhibiting CD4 help for B cells or a use a different mechanism.
Moreover, in defining a compounds mechanism of action, it is
possible that underlying mechanisms of disease pathogenesis
may also be revealed.
References
[1] D. Kabelitz, R. Medzhitov, Innate immunity—cross-talk with
adaptive immunity through pattern recognition receptors and
cytokines, Curr. Opin. Immunol. 19 (2007) 1–3.
[2] J.P. Messina, G.S. Gilkeson, D.S. Pisetsky, Stimulation of in
vitro murine lymphocyte proliferation by bacterial DNA, J.
Immunol. 147 (1991) 1759–1764.
[3] D.M. Klinman, A.K. Yi, S.L. Beaucage, J. Conover, A.M.
Krieg, CpG motifs present in bacteria DNA rapidly induce
lymphocytes to secrete interleukin 6, interleukin 12, and
interferon gamma, Proc. Natl. Acad. Sci. U. S. A. 93 (1996)
2879–2883.
[4] A.M. Krieg, CpG motifs in bacterial DNA and their immune
effects, Annu. Rev. Immunol. 20 (2002) 709–760.
[5] I. Gursel, M. Gursel, H. Yamada, K.J. Ishii, F. Takeshita, D.M.
Klinman, Repetitive elements in mammalian telomeres suppress
bacterial DNA-induced immune activation, J. Immunol. 171
(2003) 1393–1400.
[6] L. Dong, S. Ito, K.J. Ishii, D.M. Klinman, Suppressive oligonu-
cleotides protect against collagen-induced arthritis in mice,
Arthritis Rheum. 50 (2004) 1686–1689.
[7] L. Dong, S. Ito, K.J. Ishii, D.M. Klinman, Suppressive oligodeox-
ynucleotides delay the onset of glomerulonephritis and prolong
survival in lupus-prone NZB×NZW mice, Arthritis Rheum. 52
(2005) 651–658.
[8] P. Bennett, Demystified … microsatellites, Mol. Pathol. 53
(2000) 177–183.
[9] R. Sun, L. Sun, M. Bao, Y. Zhang, L.Wang, X.Wu, D. Hu, Y. Liu, Y.
Yu, A humanmicrosatellite DNA-mimicking oligodeoxynucleotide
with CCT repeats negatively regulates TLR7/9-mediated innate
immune responses via selected TLR pathways, Clin. Immunol. 134
(2010) 262–276.
[10] M.K. Crow, K.A. Kirou, Interferon-alpha in systemic lupus
erythematosus, Curr. Opin. Rheumatol. 16 (2004) 541–547.
[11] C. He, Z. Lei, R. Sun, T. Zhao, Y. Zhang, Y. Fu, L. Wang, Y. Yu,
Effects of oligodeoxynucleotidewithCCT repeats on chronic graft
versus host disease induced experimental lupus nephritis inmice,
Clin. Immunol. 140 (2011) 300–306.
[12] J.P. Portanova, F.M. Ebling, W.S. Hammond, B.H. Hahn, B.L.
Kotzin, Allogeneic MHC antigen requirements for lupus-like
autoantibody production and nephritis in murine graft-vs-host
disease, J. Immunol. 141 (1988) 3370–3376.
[13] R. Eisenberg, The chronic graft-versus-host model of systemic
autoimmunity, Curr. Dir. Autoimmun. 6 (2003) 228–244.
[14] C.S. Via, Advances in lupus stemming from the parent-into-F1
model, Trends Immunol. 31 (2010) 236–245.
[15] S.C.Morris, R.L.Cheek,P.L.Cohen,R.A. Eisenberg,Autoantibodies
in chronic graft versus host result from cognate T–B interactions,
J. Exp. Med. 171 (1990) 503–517.
[16] E. Gleichmann, H. Gleichmann, Pathogenesis of graft-versus-
host reactions (GVHR) and GVH-like diseases, J. Invest.
Dermatol. 85 (1985) 115s–120s.
[17] I. Puliaeva, R. Puliaev, C.S. Via, Therapeutic potential of CD8+
cytotoxic T lymphocytes in SLE, Autoimmun. Rev. (2008) 219–223.
[18] J.R. Tschetter, E. Mozes, G.M. Shearer, Progression from acute
to chronic disease in a murine parent-into-F1 model of graft-
versus-host disease, J. Immunol. 165 (2000) 5987–5994.
[19] A.D. Foster, M. Haas, I. Puliaeva, K. Soloviova, R. Puliaev, C.S.
Via, Donor CD8 T cell activation is critical for greater renal
disease severity in female chronic graft-vs.-host mice and is
associated with increased splenic ICOS(hi) host CD4 T cells and
IL-21 expression, Clin. Immunol. 136 (2010) 61–73.
[20] C.S. Via, S.O. Sharrow, G.M. Shearer, Role of cytotoxic T
lymphocytes in the prevention of lupus-like disease occurring in
a murine model of graft-vs-host disease, J. Immunol. 139 (1987)
1840–1849.
[21] D. De Wit, M. Van Mechelen, C. Zanin, J.M. Doutrelepont, T.
Velu, C. Gerard, D. Abramowicz, J.P. Scheerlinck, P. De
Baetselier, J. Urbain, et al., Preferential activation of Th2 cells
in chronic graft-versus-host reaction, J. Immunol. 150 (1993)
361–366.
[22] S.L. Reiner, R.M. Locksley, The regulation of immunity to
Leishmania major, Annu. Rev. Immunol. 13 (1995) 151–177.
[23] G.R. Brown, E.L. Lee, D.L. Thiele, TNF enhances CD4+ T cell
alloproliferation, IFN-gamma responses, and intestinal graft-
versus-host disease by IL-12-independent mechanisms,
J. Immunol. 170 (2003) 5082–5088.
[24] V. Rus, A. Svetic, P. Nguyen, W.C. Gause, C.S. Via, Kinetics of
Th1 and Th2 cytokine production during the early course of
acute and chronic murine graft-versus-host disease. Regulatory
role of donor CD8+ T cells, J. Immunol. 155 (1995) 2396–2406.
[25] A.D. Foster, K. Soloviova, I. Puliaeva, M. Puliaiev, R. Puliaev, F.
Finkelman, C.S. Via, Donor CD8 T cells and IFN-{gamma} are
critical for sex-based differences in donor CD4 T cell engraft-
ment and lupus-like phenotype in short-term chronic graft-
versus-host disease mice, J. Immunol. 186 (2011) 6238–6254.
[26] M.K. Gately, L.M. Renzetti, J. Magram, A.S. Stern, L. Adorini,
U. Gubler, D.H. Presky, The interleukin-12/interleukin-12-
receptor system: role in normal and pathologic immune
responses, Annu. Rev. Immunol. 16 (1998) 495–521.
[27] J.M. Curtsinger, M.F. Mescher, Inflammatory cytokines as a
third signal for T cell activation, Curr. Opin. Immunol. 22 (2010)
333–340.
[28] M. Azuma, H. Yssel, J.H. Phillips, H. Spits, L.L. Lanier,
Functional expression of B7/BB1 on activated T lymphocytes,
J. Exp. Med. 177 (1993) 845–850.
[29] M.R. Prabhu Das, S.S. Zamvil, F. Borriello, H.L. Weiner, A.H.
Sharpe, V.K. Kuchroo, Reciprocal expression of co-stimulatory
molecules, B7-1 and B7-2, on murine T cells following
activation, Eur. J. Immunol. 25 (1995) 207–211.
[30] J.P. Weintraub, R.A. Eisenberg, P.L. Cohen, Up-regulation of
Fas and the costimulatory molecules B7-1 and B7-2 on
peripheral lymphocytes in autoimmune B6/gld mice, J.
Immunol. 159 (1997) 4117–4126.
[31] J. Verwilghen, R. Lovis,M.DeBoer, P.S. Linsley,G.K.Haines, A.E.
Koch, R.M. Pope, Expression of functional B7 and CTLA4 on
rheumatoid synovial T cells, J. Immunol. 153 (1994) 1378–1385.
[32] I. Puliaeva, K. Soloviova, M. Puliaiev, T. Lang, R. Puliaev, C.S.
Via, Enhancement of suboptimal CD8 cytotoxic T cell effector
function in vivo using antigen-specific CD80 defective T cells,
J. Immunol. 186 (2011) 291–304.
[33] T.J. Lang, P. Nguyen, R. Peach, W.C. Gause, C.S. Via, In vivo
CD86 blockade inhibits CD4+ T cell activation, whereas CD80
blockade potentiates CD8+ T cell activation and CTL effector
function, J. Immunol. 168 (2002) 3786–3792.
[34] R. Puliaev, I. Puliaeva, L.A. Welniak, A.E. Ryan, M. Haas, W.J.
Murphy, C.S. Via, CTL-promoting effects of CD40 stimulation
outweigh B cell-stimulatory effects resulting in B cell elimina-
tion and disease improvement in a murine model of lupus, J.
Immunol. 181 (2008) 47–61.
214 EDITORIAL
[35] M.A. Williams, M.J. Bevan, Effector and memory CTL differen-
tiation, Annu. Rev. Immunol. 25 (2007) 171–192.
[36] R.K. Dinesh, B.J. Skaggs, A. La Cava, B.H. Hahn, R.P. Singh, CD8+
Tregs in lupus, autoimmunity, and beyond, Autoimmun. Rev. 9
(2010) 560–568.
[37] H.J. Kim, B. Verbinnen, X. Tang, L. Lu, H. Cantor, Inhibition of
follicular T-helper cells by CD8(+) regulatory T cells is essential
for self tolerance, Nature 467 (2010) 328–332.
[38] H.J. Kim, X. Wang, S. Radfar, T.J. Sproule, D.C. Roopenian, H.
Cantor, CD8+ T regulatory cells express the Ly49 Class I MHC
receptor and are defective in autoimmune prone B6-Yaa mice,
Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 2010–2015.
Charles S. Via
Pathology Department,
Uniformed Services University of Health Sciences,
Bethesda, MD 20851, USA
E-mail address: cvia@usuhs.mil.
215EDITORIAL
